Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Revenue (2022 - 2025)

ARS Pharmaceuticals' Revenue history spans 4 years, with the latest figure at $28.1 million for Q4 2025.

  • For Q4 2025, Revenue fell 67.56% year-over-year to $28.1 million; the TTM value through Dec 2025 reached $84.3 million, down 5.46%, while the annual FY2025 figure was $84.3 million, 5.46% down from the prior year.
  • Revenue for Q4 2025 was $28.1 million at ARS Pharmaceuticals, down from $32.5 million in the prior quarter.
  • Across five years, Revenue topped out at $86.6 million in Q4 2024 and bottomed at $10000.0 in Q2 2023.
  • The 4-year median for Revenue is $1.4 million (2022), against an average of $14.6 million.
  • The largest annual shift saw Revenue tumbled 97.84% in 2023 before it surged 4900.0% in 2024.
  • A 4-year view of Revenue shows it stood at $189000.0 in 2022, then plummeted by 94.71% to $10000.0 in 2023, then soared by 865710.0% to $86.6 million in 2024, then tumbled by 67.56% to $28.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Revenue are $28.1 million (Q4 2025), $32.5 million (Q3 2025), and $15.7 million (Q2 2025).